Cisplatin pk

Author: leqc

August undefined, 2024

WebSep 15, 2024 · DESCRIPTION. Cisplatin Injection (cisplatin injection (cisplatin (cisplatin injection) injection) ) is a sterile aqueous solution, available in 50, 100 and 200 mL … WebJun 21, 2024 · Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival.

Pharmaceutics Free Full-Text Machine-Learning Exploration of ...

WebAdministration of a nephrotoxic drug such as cisplatin can be used to cause renal dysfunction as an approach to mimic human serum levels of renally excreted drugs. We aimed to determine the dose of cisplatin that did not affect the survival rate of mice and to achieve human-like serum concentrations of cefepime. WebApr 14, 2024 · Moreover, in cisplatin-induced renal injury models, they also reduced serum blood urea nitrogen (BUN) and creatinine levels to different degrees, the best of which was 6-methylflavone. The pharmacophore model clarified that the aromatic ring, hydrogen bond acceptors, and hydrogen bond donors might play a vital role in the inhibitory effect of ... geoff cottam

Development and validation of a LC–MS/MS assay for …

WebJun 21, 2024 · Cisplatin was administered at a dose of 80 mg per square meter of body-surface area in a continuous intravenous 6-hour infusion for four preoperative and two postoperative courses at 14-day... WebNov 18, 2024 · Individual pharmacokinetics (PK) parameters of Cisplatin were identified using a Bayesian approach. Nephrotoxicity and ototoxicity were considered as typical Cisplatin-related toxicities according to Common Terminology Criteria for Adverse Events (CTCAE) standards. chris leonard wjbr

Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells

Cetuximab pharmacokinetic/pharmacodynamics relationships in …

WebWe aimed to evaluate cisplatin pharmacokinetics (PK) and the exposure to unbound cisplatin in SCLC patients using the informative priors, and assess the relationship between the cisplatin... WebOct 7, 2024 · Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of pediatric and adult malignances. However, it has various side effects which limit its use. Cisplatin mouse models are widely used in studies investigating cisplatin therapeutic and toxic effects. geoff cottrill linkedinWebOct 7, 2024 · In addition, significant immune cell infiltration was observed in the kidney after four doses of 9 mg/kg cisplatin, contrary to what has been previously reported. These … geoff cottrill instagram

"WebCISPLATIN Although they are members of the same chemical family, cis- platin is considered to be superior therapy for speciﬁctumor … " - Cisplatin pk

Cisplatin pk

Quantitative prediction of human pharmacokinetic responses to

WebFinally, we discovered that integrin α6β4 preferentially activated DNA-PK, facilitated DNA-PK-p53 and p53-53BP1 complex formation in response to cisplatin and required DNA-PK to enhance ATM, 53BP1 and p53 activation as well as cisplatin sensitivity. In summary, we discovered a novel function of integrin α6β4 in promoting cisplatin ... WebSerial plasma samples for PK analysis were obtained at intervals before and after the administration of capecitabine and cisplatin on Day 1. Results: Twenty-two patients were enrolled in this PK study: eight in the HXP arm and 14 in the XP arm. All blood samples were available for PK analysis.

Did you know?

WebDec 15, 2012 · OSTI.GOV Journal Article: Cisplatin Pharmacokinetics in Nontumoral Pig Liver Treated With Intravenous or Transarterial Hepatic Chemoembolization Cisplatin Pharmacokinetics in Nontumoral Pig Liver Treated With Intravenous or Transarterial Hepatic Chemoembolization Full Record Related Research Abstract WebMar 1, 2024 · Cisplatin (Platinol ®) is a chemotherapeutic agent, first approved by the U.S. Food and Drug Administration (FDA) in 1978 for the treatment of ovarian cancer and finds its use nowadays for the treatment of various types of cancer including cervical cancer, testicular cancer and germ cell tumors [1].

WebJan 27, 2024 · Fig. 4: Prediction of cisplatin PK and PD parameters using the multi-organ-chip IVIVT system. a, The fluidic coupling path of the bone marrow, liver and kidney chips linked to the AV reservoir in ... WebMar 1, 1998 · Although cisplatin has been used extensively for the treatment of solid tumors, the best administration schedule has not been decided yet. The majority of …

WebFurther, cisplatin (CDDP)-resistant FaDu cells displayed stem-like features and higher CD44, ABCB1 and ADAM17 expression. Higher autophagic flux and mitophagy were observed in resistant FaDu cells as compared to parental cells, and inhibition of autophagy led to the decrease in stemness, restoration of mitochondrial proteins and reduced ... WebNational Center for Biotechnology Information

WebJun 15, 1987 · The plasma clearance of free cisplatin (26.1 ml/min/kg) was significantly greater than that of either Carboplatin (10.3 ml/min/kg) or insulin (10.1 ml/min/kg). The main route of excretion of the two platinum complexes was via the urine, with 80-90% of Carboplatin and 43-48% of cisplatin being excreted within 4 hr.

WebCarboplatin shares some of the therapeutic advantages of cisplatin, but without a significant incidence of the dose-limiting neurotoxicity and nephrotoxicity which is experienced with cisplatin. However, its use is associated with dose-limiting bone marrow suppression. Carboplatin is present in the blood as 3 distinct species. geoff cottrill topgolfWebDec 31, 2008 · The cisplatin dose was 75 mg/m 2 for all cohorts and the pemetrexed dose was increased in increments of 100 mg/m 2 for subsequent cohorts. Treatment and dose escalation scheme. Pemetrexed and cisplatin were administered on day 1 of a 21-d cycle as i.v. infusions of 10 and 60 min, respectively. chris leong fasspayWebApr 4, 2024 · PK was determined by LC-MS/MS, and PD included methemoglobin levels at 4 h post dose. Within patient PK variability after IV and PO dosing and PO bioavailability were calculated. Results: PK data were available for 10 patients at 100 (the MTD) and 150 mg. PO parameter values were T max 1.3 h, t 1/2 1.4 h, CL/F 104 L/h, and V z /F 214 L. geoff couchWebFeb 16, 2024 · Generic name: cisplatin [ sis-PLA-tin ] Brand names: Platinol, Platinol-AQ, Platinol (Restricted Access) Dosage forms: intravenous powder for injection (50 mg), … geoff courtnall elite prospectsWebConclusion: TGF-β induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide. Further study is needed to confirm our findings in other growth factor-induced cells, as well as in in vivo model. Keywords: TMEPAI, TGF-β, doxorubicin, paclitaxel. chris leong appointmentWebVorbeugung der durch Cisplatin-Chemotherapie induzierten Ototoxizität; Neue Medikamente zur Zulassung empfohlen: Bimervax (COVID-19-Impfstoff [rekombinant, adjuvant]): ist als Booster für die aktive Immunisierung zur Vorbeugung von COVID-19 bei Personen ab 16 Jahren indiziert, die zuvor einen mRNA-COVID-19-Impfstoff erhalten … geoffcourtney207 gmail.comWebMethods: An ancillary pharmacokinetics (PK) exploration was performed in the context of a prospective study investigating circulating-tumour cells vs progression-free survival (PFS). Cetuximab plasma concentrations were analysed according to a population PK model. geoff courtnall dating